RecruitingPHASE1, PHASE2NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Studying Plasma cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Intervention
- Sonrotoclax(drug)
- Enrollment
- 246 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- City of Hope Irvine Lennar, Irvine, California, United States
- University of Miami, Miami, Florida, United States
- Emory University Winship Cancer Center, Atlanta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York, United States
- Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus, Ohio, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- University of Washington, Seattle, Washington, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04973605 on ClinicalTrials.govOther trials for Plasma cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami
- RECRUITINGPHASE1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal
- RECRUITINGPHASE3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPHASE1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin
- RECRUITINGPHASE2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGPHASE2NCT06822972HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc.
- RECRUITINGNANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic